Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$9.28−0.22 (-2.37%)
Close on Nov 17, 2026Market cap $596.89MP/E –Yield –
Cullinan Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Cullinan Therapeutics's total assets was $322.56M at Sep 30, 2026. For fiscal 2025 it was $448.37M, down 27.9% from the year before. The highest annual figure on record is $621.82M in fiscal 2024.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $448.37M | -27.9% |
| FY2024 | Dec 31, 2024 | $621.82M | +28.4% |
| FY2023 | Dec 31, 2023 | $484.18M | -13.7% |
| FY2022 | Dec 31, 2022 | $561.12M | +28.3% |
| FY2021 | Dec 31, 2021 | $437.19M | +103.6% |
| FY2020 | Dec 31, 2020 | $214.71M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $322.56M | -33.4% |
| Q2 FY2026 | Jun 30, 2026 | $363.79M | -30.1% |
| Q1 FY2026 | Mar 31, 2026 | $402.98M | -30.5% |
| Q4 FY2025 | Dec 31, 2025 | $448.37M | -27.9% |
| Q3 FY2025 | Sep 30, 2025 | $484.13M | -25.9% |
| Q2 FY2025 | Jun 30, 2025 | $520.33M | -23.6% |
| Q1 FY2025 | Mar 31, 2025 | $579.68M | +29.0% |
| Q4 FY2024 | Dec 31, 2024 | $621.82M | +28.4% |
| Q3 FY2024 | Sep 30, 2024 | $653.25M | +32.0% |
| Q2 FY2024 | Jun 30, 2024 | $681.22M | +30.5% |
| Q1 FY2024 | Mar 31, 2024 | $449.43M | -12.7% |
| Q4 FY2023 | Dec 31, 2023 | $484.18M | -13.7% |
| Q3 FY2023 | Sep 30, 2023 | $494.71M | -19.9% |
| Q2 FY2023 | Jun 30, 2023 | $521.98M | -21.8% |
| Q1 FY2023 | Mar 31, 2023 | $514.99M | +17.7% |
| Q4 FY2022 | Dec 31, 2022 | $561.12M | +28.3% |
| Q3 FY2022 | Sep 30, 2022 | $617.24M | +36.1% |
| Q2 FY2022 | Jun 30, 2022 | $667.25M | +43.7% |
| Q1 FY2022 | Mar 31, 2022 | $437.46M | -8.8% |
| Q4 FY2021 | Dec 31, 2021 | $437.19M | +103.6% |
| Q3 FY2021 | Sep 30, 2021 | $453.40M | – |
| Q2 FY2021 | Jun 30, 2021 | $464.35M | – |
| Q1 FY2021 | Mar 31, 2021 | $479.67M | – |
| Q4 FY2020 | Dec 31, 2020 | $214.71M | – |
See a number that looks wrong?